Business, energy, technology, markets and global industry news from Business News Today

Camzyos

PharmaDeviceNews Camzyos
Representative image: A cardiologist reviews heart imaging as Cytokinetics’ $CYTK aficamten gains UK approval and NICE backing for approximately 6,600 adults with symptomatic obstructive hypertrophic cardiomyopathy.
Pharma & Biotech

Bristol Myers Squibb Camzyos franchise reaches $1.15bn as pediatric evidence expands

Camzyos maintained lower heart obstruction through 56 weeks in adolescents as Bristol Myers Squibb expands a $1.15 billion HCM franchise.

Read More
Pharma & Biotech

Edgewise Therapeutics’ Phase 2 HCM data put systolic function into sharper focus

Find out how Edgewise Therapeutics’ EDG-7500 data could reshape HCM drug development as Phase 3 questions emerge.

Read More